- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Clifford Goodman Outlines the Pros and Cons of NCCN Guidelines
Over the years, the National Comprehensive Cancer Network Guidelines have become the market leader for clinical guidelines to consult, but with that success comes responsibility and scrutiny, according to Clifford Goodman, PhD.
Over the years, the National Comprehensive Cancer Network (NCCN) Guidelines have become the market leader for clinical guidelines to consult, but with that success comes responsibility and scrutiny, according to Clifford Goodman, PhD, senior vice president and director at the Center for Comparative Effectiveness Research at The Lewin Group.
NCCN has been successful because it can quickly update its Guidelines and it is easy to access. However, the biggest drawback does not have to do with the content, but how the guidelines are being used.
“Most patients consider they have insufficient information upon which to base decisions at the time they’ve got to make those decisions,” Dr Goodman said.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
